Ocuphire Pharma
primary achieved in two registration phase trials | Ocuphire Pharma
Company
Deck Type
Deck date
March 2022
Slide
18 of 38
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Results
March 2022
mean pupil diameter over time by eye color | Ocuphire Pharma
Results
March 2022
mean pupil diameter over time by mydriatic agents | Ocuphire Pharma
Results
March 2022
mean pupil diameter over time | Ocuphire Pharma
Results
March 2022
comparison of one drop fellow eye with two drops study eye | Ocuphire Pharma
Related slides by other companies
BioNTech
Results
November 2020
covid vaccine development | BioNTech
ATAI
Investor Presentation
October 2023
in cash as of provides expected runway into life sciences operational focus program guidance | ATAI
ATAI
Investor Presentation
March 2023
achieved and expected milestones phase data phase data phase first subject dosed phase data anorexia key achievements to date phase data phase data initiation of clinical programs phase data phase a data phase data phase data phase data summer phase study data in cash as of plus access to up to an additional from term loan facility provides runway expected into we expect deliver several meaningful anticipated across our through with | ATAI
Oculis
Results
May 2023
next step phase trial stage | Oculis
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights